日本薬理学会年会要旨集
Online ISSN : 2435-4953
第93回日本薬理学会年会
セッションID: 93_1-YIA-13
会議情報

年会優秀発表賞(YIA)候補演題
細胞性粘菌由来分化誘導因子DIF-1はSTAT3を介してcyclin D1を減弱することで乳癌細胞の増殖を抑制する
*哲翁 ふみ有岡 将基高橋 富美西村 英紀笹栗 俊之
著者情報
キーワード: cancer, cell growth, kinase
会議録・要旨集 オープンアクセス

詳細
抄録

Differentiation-inducing factor-1 (DIF-1) identified from Dictyostelium inhibits the proliferation of various cancer cells. However, the precise mechanism of DIF-1's action remains undetermined. Here, we investigated whether DIF-1 prevents tumor growth in vivo and how DIF-1 inhibits cell proliferation using breast cancer MCF-7 and 4T1 cells.

First, we performed experiments using cancer model mice made by injecting the cells into mammary fat pad. Oral administration of DIF-1 significantly suppressed the primary tumor growth without adverse effects.

DIF-1 strongly suppressed the proliferation of MCF-7 and 4T1 cells reducing the expression levels of STAT3 and cyclin D1. S3I-201, a STAT3 inhibitor, and the siRNA for STAT3 reduced cyclin D1 and inhibited cell proliferation, indicating that the reduction of cyclin D1 was caused by the reduction of STAT3. In MCF-7 cells, DIF-1 did not reduce STAT3 mRNA or promote STAT3 protein degradation, suggesting that DIF-1 inhibited STAT3 protein synthesis. We revealed that DIF-1 inhibited the phosphorylation (activation) of p70S6K/p85S6K. Inhibition of p70S6K/p85S6K using rapamycin, an mTOR inhibitor, also reduced the expressions of STAT3 and cyclin D1.

In conclusion, DIF-1 exhibits anti-proliferative effect by reducing STAT3-mediated cyclin D1 in breast cancer cells. The inhibition of STAT3 by DIF-1 was caused by the suppression of protein synthesis through the inhibition of p70S6K/p85S6K. Our findings suggest that a novel anti-cancer agent against breast cancer could be developed using DIF-1 as a lead compound.

著者関連情報
© 2020 本論文著者
前の記事 次の記事
feedback
Top